News

Company announced it has filed a motion for preliminary injunction to stop Aria from making, using, selling or offering for sale, importing or exporting, infringing tests for detecting fetal chromosomal aneuploidy.

Company has named Miguel Motta as its chief operating officer. Motta will be responsible for the strategic and operational leadership of the company’s business development, global operations, marketing and human resources organization.

An important new study by a team of scientists at RhinoCyte™ Inc., Louisville, Ky., details promising results on the effectiveness of olfactory (nasal) stem cells in repairing spinal cord damage resulting from the most common cause of these injuries.

Agreement significantly expands the companies' successful pilot program to develop unique patient-derived tumor xenografts (PDX), through the use of Molecular Response's proprietary 'living' cell bank of primary tumor cells.

Since it is now clear that fragments can be developed into clinical candidates, the discussion is shifting to the design of good-quality lead compounds from fragment hits.

Under the agreement, Mexico Diffractia will promote and sell a range of Mitegen’s product lines in Mexico.

Researchers from the Scripps Research Institute have utilized X-ray crystallography to determine the structure of P450 2D6 complexed with a substrate and potent inhibitor prinomastat to 2.85 Å resolution.

Company announces the completion of a worldwide license from Cooperative Diagnostics to use its suite of patents and expertise for the development of its growing pipeline of molecular diagnostic kits.

This article presents a novel ChIP-seq workflow for the archaea using the model organism Halobacterium salinarum sp. NRC-1 (Hb. NRC-1) and demonstrates its application for mapping the genome-wide binding sites of natively expressed transcription factors.

David Cameron opens Company’s new drug discovery centre at Long Hanborough.